To determine whether IFN-γ was responsible for the hypoglycemia in the anti-CD3 treated animals, firstly, we injected recombinant mouse IFN-γ at a dose of doubled average serum level of IFN-γ six hours after anti-CD3 treatment (shown in Figure 5(a)), we failed to observe any difference between IFN-γ and PBS treated groups through 24 hours' observation (data not shown). The gene discussed is IFNG; the disease is Hypoglycemia.